Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

• Published in: Advances in rheumatology (London, England) Vol. 63; no. 1; p. 15
• Main Authors: Molica Colella, Francesco, Zizzo, Gaetano, Parrino, Vincenzo, Filosa, Maria Teresa, Cavaliere, Riccardo, Fazio, Francesco, Molica Colella, Aldo Biagio, Mazzone, Antonino
• Format: Journal Article
• Language: English
• Published: England BioMed Central 27.03.2023; Sociedade Brasileira de Reumatologia; BMC
• Subjects: Adult; Ankylosing spondylitis; Ankylosing Spondylitis (AS); Arthritis, Psoriatic - drug therapy; ASDAS-CRP; Body weight; Clinical outcomes; Clinical trials; DAS28-CRP; Disease; Drug dosages; Female; Humans; Interleukin-17 (IL-17); Italy; Male; Male sex; Mann-Whitney U test; Medical records; Nonsteroidal anti-inflammatory drugs; Patients; Psoriatic arthritis; Quality of life; Remission; Remission (Medicine); Retrospective Studies; RHEUMATOLOGY; Spondylitis, Ankylosing - drug therapy; Statistical analysis; Italy; Male sex; ASDAS-CRP; Treatment; Body weight; Secukinumab; Interleukin-17 (IL-17); DAS28-CRP; Psoriatic Arthritis (PsA); Spondyloarthritis (SpA); Ankylosing Spondylitis (AS)
• ISSN: 2523-3106; 2523-3106
• DOI: 10.1186/s42358-023-00295-2

Secukinumab has shown high efficacy in randomized controlled trials in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Here, we investigated its real-life effectiveness and tolerability in a cohort of AS and PsA patients. We retrospectively analyzed medical records of outpatients with AS or PsA treated with secukinumab between December 2017 and December 2019. ASDAS-CRP and DAS28-CRP scores were used to measure axial and peripheral disease activity in AS and PsA, respectively. Data were collected at baseline and after 8, 24, and 52 weeks of treatment. Eighty-five adult patients with active disease (29 with AS and 56 with PsA; 23 males and 62 females) were treated. Overall, mean disease duration was 6.7 years and biologic-naïve patients were 85%. Significant reductions in ASDAS-CRP and DAS28-CRP were observed at all time-points. Body weight (in AS) and disease activity status at baseline (particularly in PsA) significantly affected disease activity changes. ASDAS-defined inactive disease and DAS28-defined remission were achieved in comparable proportions between AS and PsA patients, at both 24 weeks (45% and 46%) and 52 weeks (65.5% and 68%, respectively); male sex was found an independent predictor of positive response (OR 5.16, P = 0.027). After 52 weeks, achievement of at least low disease activity and drug retention were observed in 75% of patients. Secukinumab was well-tolerated and only mild injection-site reactions were recorded in 4 patients. In a real-world setting, secukinumab confirmed great effectiveness and safety in both AS and PsA patients. The influence of gender on treatment response deserves further attention.